Budesonide/Formoterol in the Management of Patients with Mild or Moderate Asthma: Clinical Research
- VernacularTitle:布地奈德/福莫特罗治疗轻、中度哮喘临床研究
- Author:
Juxiang ZHANG
;
Xiuling GAO
;
Shuhong LIU
;
Suyin LI
;
Zhaobo CUI
- Publication Type:Journal Article
- Keywords:
Asthma;
Inhalation therapy;
Budesonide/formoterol;
Budesonide dry powder
- From:
China Pharmacy
2007;0(26):-
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE: To evaluate the efficacy and the safety of low dose budesonide/formoterol combination therapy vs.medium dose of budesonide(BUD) dry powder in the management of mild or moderate adult asthma.METHODS: A total of 62 patients with asthma were randomized to Group A(budesonide plus formcterol) or Group B(budesonide).Main outcome measures: daytime symptom and nocturnal symptom,peak expiratory flow(PEF),number of times of using rapid-acting ? 2 agonist and its ADR.RESULTS: After treatment,both groups had significant improvement in daytime symptom and nocturnal symptom(number of times of wakeup),PEF value and lung function,and the dosage of rapid-acting ? 2 agonist was decreased,showing significant differences between the two groups.The ADR was light in degree.CONCLUSION: Inhalation therapy of low dose of glucocorticoid plus long-acting ? 2 agonist is an optimal choice in the management of asthma.The efficacy of glucocorticoid could be enhanced more by combination with low dose and long-acting ? 2 agonist than by simply increasing its own dose.
